What Virscio does

Virscio is a specialty contract research organization (CRO) that provides preclinical and translational research services for therapeutic development across CNS, ophthalmology, cardiovascular, metabolic, and gene/cell therapy indications. Founded in 2002 and co-led by Matthew Lawrence, MD/PhD (CEO/CSO) and Christopher Stanley (CBO/CFO), the company serves global pharmaceutical companies, venture-backed biotechnology companies, and academic and government research institutions through formal RFP-based engagements. Its core customer problems are the translational gap between rodent preclinical models and human clinical outcomes, restricted NHP supply at incumbent CROs, and the high cost and timeline of IND-enabling programs.

The company's technical platform is built around three integrated cores: an in vivo nonhuman primate (NHP) vivarium in St. Kitts, West Indies, populated by African green monkeys sourced from a unique island population of 35,000+ animals and managed through a direct partnership with the St. Kitts government; a digital histopathology and tissue pharmacodynamics core in New Haven, CT, featuring AI-enabled image analysis (Visiopharm), immunohistochemistry, and pathology interpretation; and a molecular biology core offering qPCR/ddPCR, ELISA, RNA-Seq, single-cell sequencing, and western blots. The St. Kitts green monkey is the central asset — it is biologically clean (low AAV neutralizing antibody prevalence, free of continental NHP zoonoses), evolutionarily close to humans, and materially cheaper (~1/3) than cynomolgus macaques. Virscio has 30+ validated disease models, GLP compliance since 2008, AAALAC accreditation since 2010, and 60+ peer-reviewed publications in journals including Nature and Science Translational Medicine.

Virscio generates revenue through fee-for-service contract research, with multi-year engagements spanning early proof-of-concept studies through GLP-compliant IND-enabling toxicology, safety pharmacology, biodistribution, and efficacy studies. Go-to-market is direct enterprise field sales led by the CBO and business development team, augmented by a "no-risk engagement model" that provides study design and budget preparation at no cost to prospective clients. The company does not publicly disclose pricing, operates with no channel partners or resellers, and serves a globally distributed client base from its two facilities in New Haven, CT and St. Kitts. The launch of its Pathology and Tissue Pharmacodynamics Services Division in 2025 expanded the platform beyond in vivo services into integrated histology and image analysis.

Name

Virscio

Legal name

Virscio, Inc.

Website

https://virscio.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Virscio is a specialty contract research organization providing preclinical translational research services using African green monkeys from St. Kitts. It serves biotech, pharmaceutical, and academic clients worldwide with integrated in vivo, digital histopathology, and molecular biology capabilities.

Ownership category

akta.pro rank

Headquarters

HQ city

Hamden

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Contract Research Services (CRO): Virscio operates as a specialty contract research organization (CRO) providing preclinical and translational research services. Revenue is generated through fee-for-service contracts for study design, execution, sample processing, data analysis, and reporting. Engagements range from early proof-of-concept studies to GLP-compliant IND-enabling studies. Clients include biotech, pharma, and academic institutions worldwide.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Virscio is a specialty contract research organization that provides preclinical and translational research services using African green monkeys (nonhuman primates from St. Kitts), supported by integrated digital histopathology with AI-enabled image analysis and molecular biology services. The company designs and executes GLP-compliant IND-enabling studies, efficacy studies, safety pharmacology, biodistribution, and pharmacokinetic/pharmacodynamic studies for biotech, pharmaceutical, and academic clients worldwide.

Product overview

Virscio is a specialty translational research organization providing preclinical and translational research services, in vivo nonhuman primate disease modeling, and related histopathology services. The company operates a fully integrated platform combining in vivo NHP research services (using African green monkeys from St. Kitts), digital histopathology and histomolecular services, and molecular biology services. Core service areas include GLP toxicology, safety pharmacology, gene and cell therapy services, and CNS/translational research. The company maintains specialized expertise across therapeutic areas including CNS, ophthalmology, cardiovascular, metabolic, immunology, and gene/cell therapy, with operations in New Haven, CT and St. Kitts, West Indies.

Differentiator

Problem solved

Functional benefit

Products and services

• Nonhuman Primate Research Services In vivo preclinical research services using African green monkeys (St. Kitts green monkeys) for therapeutic development, including pharmacokinetics, pharmacodynamics, efficacy studies, and safety evaluation for biotech, pharmaceutical, and academic clients.
• Digital Histopathology Services Digital histopathology and histomolecular core supporting all tissue types and species (mouse to nonhuman primate and human), including discovery histopathology, toxicologic histopathology, and tissue pharmacodynamics with AI-enabled image analysis.
• Molecular Biology Services Molecular biology services providing mechanistic insights into disease model pathophysiology and tissue pharmacodynamics of interventions, including custom method development, biodistribution assays (qPCR, ddPCR), gene expression profiling (RNA-Seq, single cell sequencing), and western blots.
• GLP Toxicology Services GLP-compliant toxicology services from preclinical proof-of-concept to IND-enabling studies, supporting delivery and distribution, pharmacokinetics and pharmacodynamics, efficacy, and exploratory safety assessments.
• Safety Pharmacology Services Cardiovascular safety pharmacology and pharmacodynamic research including ECG, blood pressure, heart rate measurements, echocardiography, and telemetry for preclinical to IND-enabling studies.
• Gene and Cell Therapy Services Comprehensive gene and cell therapy services from preclinical proof-of-concept to IND-enabling studies, including pharmacokinetics, pharmacodynamics, delivery optimization, safety pharmacology, and biodistribution determinations.
• CNS Translational Research Services Central nervous system research services using nonhuman primates with validated test systems for proof-of-concept and candidate screening, including disease modeling for Alzheimer's, Parkinson's, stroke, and spinal cord injury.
• Pathology and Tissue Pharmacodynamics Services Division Newly launched Pathology and Tissue Pharmacodynamics Services Division offering tissue processing, slide preparation, staining, immunohistochemistry, digital slide scanning, quantitative image analysis, and pathology interpretation across GLP, non-GLP, and GCLP studies.
• VEGF-Induced Retinal Vascular Leakage Model Preclinical ophthalmology model for evaluating treatments targeting retinal vascular diseases using VEGF-induced retinal vascular permeability assessment in nonhuman primates.
• Laser-Induced CNV Models Ophthalmology disease models for age-related macular degeneration using laser-induced choroidal neovascularization for efficacy studies of anti-neovascular agents in nonhuman primates.
• Intraocular Pressure Lowering Research Glaucoma research services evaluating intraocular pressure modulation candidates using validated primate models and clinical instrumentation.
• Ocular Inflammation Research Model Anterior uveitis model induced by intracameral concanavalin A administration for evaluating anti-inflammatory agents and efficacy of test compounds in nonhuman primates.
• Laser-Induced Glaucoma Model Chronic ocular hypertension model using laser scarification for evaluating IOP-lowering and neuroprotective agents with RNFL, optic nerve head, and neuroretina assessments in nonhuman primates.

Quantifiable outcome

• Enrolling a naive St. Kitts green monkey costs approximately 1/3 the cost of a cynomolgus monkey, translating into significantly lower overall study costs
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• St. Kitts Government (Ministry of Agriculture)coreStrategic or Co-development PartnerVirscio has a direct government partnership with the St. Kitts government to humanely manage the African green monkey population on the island. This partnership enables sustainable access to a large, biologically clean NHP population for in vivo research. The population of 60,000+ monkeys presents an ecological and agricultural threat, and Virscio's research use serves as a humane population control mechanism while generating critical biomedical data.
• Specialty Third-Party Laboratories and ConsultantsminorImplementation/ SI/ Consulting PartnerVirscio regularly works with qualified specialty laboratories and consultants to execute elements of research plans not conducted directly by Virscio. Site or consultant qualification is performed by Virscio's senior scientists and quality assurance unit. Specimen shipment for analysis at third-party or sponsor laboratories is supported through temperature-controlled chain of custody with full tracking.
• UCLA Brain Research Center / Brain Atlas ProjectminorStrategic or Co-development PartnerVirscio leverages the publicly available Green Monkey Brain Atlas developed by UCLA's Brain Research Center, along with the reference genome (Ensembl Green Monkey Browser) and systems biology resources. These databases inform model characterization and cross-species comparative biology.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Charles River Laboratories: Charles River is the largest preclinical CRO globally with extensive NHP vivarium capacity and Research Models & Services, Safety Assessment, and Discovery & Safety Assessment segments. It is a broad incumbent in the same preclinical CRO space as Virscio, with overlapping GLP toxicology, safety pharmacology, and NHP services but a much larger global footprint and broader service menu.
• Labcorp (Drug Development / Covance): Labcorp Drug Development (formerly Covance) is a top-tier global CRO offering preclinical and clinical services including extensive NHP toxicology and safety assessment. It is a broad incumbent competitor for large pharma preclinical contracts where Virscio's smaller scale and single-island footprint may be limiting.
• Wuxi AppTec: Wuxi AppTec is a major global CRO/CDMO with significant preclinical research services including NHP-based toxicology and safety assessment. It is a broad incumbent with overlapping preclinical capabilities, particularly for biotech and pharma clients in the US and Asia.
• IQVIA: IQVIA is a leading global CRO with preclinical and clinical research services, including laboratory and safety assessment capabilities. It is a broad incumbent competitor for enterprise pharma CRO contracts, though its preclinical NHP footprint is more limited relative to its clinical research scale.

Direct peers

• Inotiv: Inotiv is a pure-play preclinical CRO and research models provider with NHP services and contract research capabilities spanning toxicology, safety assessment, and disease modeling. It is a direct peer to Virscio as a specialty preclinical CRO serving biotech and pharma clients with NHP-dependent study offerings.
• Altasciences:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virscio